CALL US:+1-800-322-7776

Explore how Schedule III rescheduling may affect cannabis tax planning, from Section 280E and potential R&D tax credits to depreciation opportunities and the importance of allocating expenses between medical and recreational operations.

Customer-driven research is not automatically excluded from the R&D tax credit. Explore the contract terms, economic risk, and research rights CPAs should evaluate.

The R&D Tax Credit has long been one of the most powerful innovation-driven incentives in the tax code. While the core eligibility rules and definitions of qualified research expenses (QREs) have not changed, the reporting landscape has shifted, particularly with the introduction of a detailed Section G on the redesigned Form 6765.

A look at new IRS guidance on the Section 174 method change process, covering how taxpayers must coordinate 481(a) adjustments with OBBBA catch-up deductions and key Form 3115 transition relief deadlines.

This government contractor R&D tax credit guide breaks down how CPAs can identify qualifying projects under Section 41 — covering the financial risk and research rights tests, common qualifying activities, and how to spot wages, supplies, and contract research expenses across federal and SBIR/STTR work.

As businesses invest in artificial intelligence, new questions are emerging about workforce training, data security, and which AI-related activities may qualify for the R&D tax credit.

Explore how federal manufacturing tax incentives and varying state tax treatments could shape expansion, investment, and site selection decisions.

Join us for six technical webinars designed to help CPA firms navigate evolving compliance requirements, uncover overlooked planning opportunities, and strengthen advisory conversations heading into the second half of 2026.

Construction companies may be overlooking valuable R&D tax credits. Learn how qualifying design-build projects and activities can meet the requirements for the R&D tax credit.

Learn how CPA firms can identify manufacturing clients that qualify for the federal and state R&D tax credits, including qualifying activities, expenses, and common misconceptions.

Cannabis After Schedule III

Cannabis tax planning is entering a new phase as the rescheduling of certain medical cannabis products to Schedule III changes the federal tax considerations facing eligible businesses. In this episode of Let’s Talk Tax, host Dave McGuire sits down with David Seibel, EA, to discuss what the change could mean for Section 280E, potential tax credits, and business investment decisions.

The conversation explores how the treatment of eligible medical cannabis operations may affect deductions and federal tax credits, including potential research and development activities involving cultivation consistency, product formulations, purity, and process improvements. Dave and David also discuss bonus depreciation and qualified production property, along with the conditions businesses must evaluate before pursuing these opportunities.

For CPAs and business advisors, the distinction between medical and recreational operations is especially important. The discussion covers expense allocation, business licenses, entity structures, recordkeeping, and the need to prepare for additional IRS and Treasury guidance. State tax rules can also create different outcomes, making it important to evaluate each client’s circumstances rather than assume federal changes apply uniformly.

Listen to the full episode of Let’s Talk Tax to learn what cannabis businesses and their advisors should consider as they evaluate tax planning opportunities, documentation needs, and the evolving regulatory landscape.

  • SUBSCRIBE:

Latest Let's Talk Tax Episodes